Annotation Detail
Information
- Associated Genes
- ATRX
- Associated Variants
-
ATRX UNDEREXPRESSION
(
ENST00000373344.11 )
ATRX UNDEREXPRESSION ( ENST00000373344.11 ) - Associated Disease
- malignant astrocytoma
- Source Database
- CIViC Evidence
- Description
- A retrospective tumor sample study found that the loss of ATRX expression (less than 10% of nuclei) in IDH-mutant astrocytomas treated with temozolomide or a combination of procarbazine, lomustine and vincristine was associated with a greater time to treatment failure (55.6 months vs. 31.8 months; P = .0168) and a greater progression-free survival (37.1 months vs. 18.1 months; P = .038).
- Variant Origin
- N/A
- Variant Origin
- N/A
- Evidence URL
- https://civic.genome.wustl.edu/links/evidence_items/1647
- Gene URL
- https://civic.genome.wustl.edu/links/genes/525
- Variant URL
- https://civic.genome.wustl.edu/links/variants/648
- Rating
- 3
- Evidence Type
- Predictive
- Disease
- Astrocytoma
- Evidence Direction
- Supports
- Drug
- Procarbazine,Lomustine,Vincristine,Temozolomide
- Evidence Level
- B
- Pubmed
- 23904111
Drugs
Drug Name | Sensitivity | Supported |
---|---|---|
Lomustine | N/A | true |
Procarbazine | N/A | true |
Temozolomide | N/A | true |
Vincristine | N/A | true |